New drug could slash stroke risk for patients with high 'Bad' cholesterol marker

NCT ID NCT07341958

Not yet recruiting Disease control Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

First seen Jan 15, 2026 · Last updated May 24, 2026 · Updated 18 times

Summary

This study tests whether adding a new drug called Tolecilimab to standard cholesterol-lowering therapy can lower a specific blood fat called lipoprotein(a) and reduce the chance of another stroke within 90 days. The trial includes 242 adults aged 35-80 who recently had a stroke or high-risk mini-stroke and have high lipoprotein(a) levels. Participants will receive either the study drug or a placebo, and researchers will measure changes in their blood fat levels and track any new strokes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE OR HIGH-RISK TIA (ABCD² ≥ 4) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Tiantan Hopital, Capital Medical University

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ISCHEMIC STROKE OR HIGH-RISK TIA (ABCD² ≥ 4)